#China #Chengdu #Keymed Biosciences #Gastrointestinal Cancer #CM518D1

Keymed Biosciences' Breakthrough in Cancer Treatment

In the field of cancer therapy, the recent advancements by Keymed Biosciences Inc. (HKEX: 02162) have garnered significant attention across the medical community. The company has recently announced that its innovative antibody-drug conjugate (ADC), CM518D1, has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) in China. This significant step highlights Keymed's ongoing commitment to advancing oncology treatments.

Understanding CM518D1's Mechanism

CM518D1 is specifically designed to target CDH17, a member of the cadherin superfamily that is linked to various gastrointestinal cancers, including colorectal, pancreatic, gastric, and esophageal cancers. CDH17 has emerged as a crucial target because of its high expression in these cancer types and its role in tumor invasion and metastasis. By utilizing a CDH17-specific monoclonal antibody, CM518D1 effectively delivers cytotoxic agents directly to tumor cells, enhancing the specificity and potency of treatment.

Keymed's preclinical studies have shown that CM518D1 possesses strong direct cytotoxic effects, a notable bystander killing effect, and good plasma stability, further validating its potential as an effective therapy. The drug demonstrates promising anti-tumor efficacy across various solid tumor models while maintaining a favorable safety profile with a wide therapeutic window.

Clinical Trials Underway

Currently, Keymed is conducting Phase I/II clinical trials within China to evaluate the safety and preliminary efficacy of CM518D1 for patients with advanced solid tumors. These trials aim to provide critical insights into how CM518D1 can not only meet but exceed existing therapeutic options for patients suffering from gastrointestinal cancers.

The future of this initiative is geared towards establishing a reliable and precise treatment regimen for gastrointestinal cancers worldwide, emphasizing a patient-centered approach in drug development.

Keymed’s Next-Generation ADC Platform

Keymed's proprietary ADC platform is pivotal in the landscape of innovative cancer drug development. The platform showcases capabilities in crafting next-generation ADCs with distinct payloads that exhibit various mechanisms of action. Additionally, it utilizes optimized hydrophilic linkers aimed at enhancing both stability and drug delivery while engineered antibodies ensure improved binding and pharmacokinetic properties.

Keymed has further established GMP-compliant facilities to facilitate the production of linker-payload and ADC drug substances, positioning itself prominently within the ADC therapeutic development arena. This infrastructure not only demonstrates Keymed's dedication to fulfilling unmet medical needs but also reinforces its role as a leader in creating advanced therapeutic solutions for patients globally.

About Keymed Biosciences

Keymed Biosciences Inc., listed on the Hong Kong Stock Exchange, is focused on addressing urgent unmet clinical needs through innovative and accessible therapies. Founded by experts in medicine and science, the company is committed to transforming scientific achievements into commercialized products that benefit patients both in China and internationally. As the world anticipates new cancer therapies, Keymed's progress with CM518D1 stands as a beacon of hope in the ongoing battle against cancer prevalence.

With Keymed's ongoing projects and innovative approaches, there is optimism in the therapeutic landscape, significantly improving treatment avenues for gastrointestinal cancer patients and advancing the overall goal of enhancing patient care in oncology.